CAR T-cell therapy on fast track in US, EUJanuary 18, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
Drug’s label updated to include risk of allergic reactionsJanuary 17, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
Generic bortezomib available in USJanuary 13, 2018Lymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Survival differences among AYAs with blood cancersJanuary 11, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLALLHodgkin LymphomaCMLNon-Hodgkin Lymphoma
Marine animals aid development of cytotoxicity assayJanuary 11, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLCMLNon-Hodgkin LymphomaAggressive Lymphomas
Overcoming resistance to ibrutinib in CLLJanuary 9, 2018Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
DLBCL survivors at greater risk of autoimmune, infectious diseasesJanuary 3, 2018Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Brentuximab vedotin sBLA receives priority reviewJanuary 3, 2018Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Update reveals ongoing responses in ZUMA-1December 29, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Research explains why cisplatin causes hearing lossDecember 28, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Drug receives fast track, orphan designations for PTCLDecember 27, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Chemo-free combo should be option for rel/ref CLL, doc saysDecember 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Risk stratification may be possible with JCAR017December 21, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Pembrolizumab sBLA receives priority reviewDecember 16, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Primary analysis confirms interim findings of CTL019 in DLBCLDecember 15, 2017Lymphoma & Plasma Cell DisordersAggressive Lymphomas